AlertEnterprise Looks to Transform Physical Security with Reveal of New Security AI Chatbot Powered by ChatGPT
28.2.2023 17:00:00 EET | Business Wire | Press release
AlertEnterprise, Inc., the leading cyber-physical security convergence software company, today revealed the launch of its first-ever Guardian AI Chatbot powered by OpenAI ChatGPT. The company will debut the AI Chatbot globally end of March at the ASIS Europe and ISC West trade events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005630/en/
The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine. The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting. (Graphic: Business Wire)
The Guardian AI Chatbot is developed with the world-renowned GPT-3 platform created by OpenAI and is designed to instantly deliver security operators the physical access and security insights that matter most with quick questions and prompts.
“Physical security and access control systems have always contained a tremendous wealth of data but, until now, accessing it was a tedious and manual process,” said Yogesh Ailawadi, SVP Product and Solutions Engineering at AlertEnterprise. “Our Guardian AI Chatbot is poised to redefine the security operator’s experience, increasing their productivity by over 100 times with instant and actionable insights for not only risk mitigation but real business value.”
Mr. Ailawadi noted that the Guardian AI Chatbot is part of the launch of AlertEnterprise’s next-gen AI technology and is completely integrated throughout the Guardian platform.
Get powerful answers in an instant
The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine.
The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting.
Some examples are:
- “Guardian, how many people are on the Trading floor?”
- “Guardian, how many employees and visitors are in the Data Center?”
- “Guardian, how many new employee badges did we issue last month?”
- “Guardian, show me upcoming employee training expirations for restricted area access.”
Drive costs down. Boost employee efficiency.
Using Guardian and its AI Chatbot, CSO and CISO’s can exponentially boost their team’s efficiency by automating tedious tasks and freeing up time to focus on more critical responsibilities. Guardian also leverages a company’s current security investments by connecting to most leading access control vendors and over 200 out-of-the-box connectors to HR, IT and OT systems. And if the organization has a complex mix of access control systems, Guardian connects to and consolidates them all under one platform.
AlertEnterprise founder and CEO Jasvir Gill says there’s no better time for CSO and CISO’s to invest in hyper-efficiency boosting AI platforms like Guardian. “Despite economic headwinds, the world’s most forward-looking CSO and CISO’s are accelerating security digital transformation. With Guardian’s deep forensics and AI data-driven insights, CSO and CISO’s can transform their access control from the stone age to the digital age—making every part of their SOC more automated, expeditious and cost effective, and ultimately the organization more secure. That’s why I view the AlertEnterprise Guardian platform as a deflationary fighting force for companies today.”
To see a live demonstration of the Guardian AI Chatbot, visit AlertEnterprise at Stand C5 at ASIS Europe in Rotterdam, NL, and Booth #13115 at ISC West in Las Vegas, USA.
AlertEnterprise
At AlertEnterprise, cyber-physical identity and trust are at the center of everything we do. Our mission is to bring people, processes, data and technology together in a unique way to help organizations protect what matters most. We call it security convergence. And we develop game-changing security convergence solutions that deliver identity governance, access management, security intelligence and compliance validation across enterprise IT, HR, cyber and physical security environments.
AlertEnterprise is committed to using AI in a responsible and ethical manner. We recognize the importance of protecting customer data and safeguarding against potential misuse of AI technology. As such, we have implemented strict policies and procedures to ensure the ethical use of AI and to protect the privacy and security of our customers' data. We believe that transparency and accountability are critical in this regard and remain dedicated to upholding these values throughout our development and operations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005630/en/
Contact information
Willem Ryan – Senior Vice President of Marketing and Communications
Email: media@alertenterprise.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
